LENSAR appoints Michael A. Rossi as Interim CFO; annual meeting set for Aug 4, 2026

LENSAR, Inc.

Michael A. Rossi appointed Interim CFO effective May 29, 2026, via consulting agreement with Monomoy Advisors at $375/hour.
Rossi previously CFO at Access Vascular, ConcertAI, and Harvard Bioscience (Nasdaq: HBIO).
Annual meeting scheduled for Aug 4, 2026, held virtually; record date June 10, 2026.
Stockholder proposals and director nominations due by June 8, 2026.

item 5.02 item 5.08 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Michael A. Rossi

Interim Chief Financial Officer

LNSR · LENSAR, Inc.

Effective: 2026-05-29
Filed: May 29, 2026, 4:05 PM ET

On May 25, 2026, the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) appointed Michael A. Rossi to serve as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of May 29, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael A. Rossi was appointed as Interim Chief Financial Officer at LENSAR, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On May 25, 2026, the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) appointed Michael A. Rossi to serve as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of May 29, 2026.

View on SEC.gov

LENSAR, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-248230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.